Login / Signup
I’m not a doctor but I thought I knew something about anticoagulation. Over the course of a career covering cardiology I’ve written countless stories about…
Eliquis Nipping At The Heels of NOAC Market Leader Xarelto
–But the overall market for the new oral anticoagulants continues to expand. The new oral anticoagulant (NOAC) market is growing larger and is becoming increasingly…
FDA Reaffirms Safety And Efficacy Of Rivaroxaban
–FDA says no changes needed to the rivaroxaban label. Following a year of controversy and uncertainty relating to the anticoagulant drug rivaroxaban (Xarelto, Johnson &…
More Bleeding Linked To Rivaroxaban In Observational Study
–Compared to dabigatran, rivaroxaban was associated with more intracranial and other serious bleeds. A new observational study finds that patients who take rivaroxaban (Xarelto, Johnson…
More Blasts Of Concern Over ROCKET-AF
The controversy over the big Xarelto trial does not appear to be going away. A new investigation published in the BMJ raises more troubling questions…
ROCKET AF Investigators Say New Analysis Supports Original Trial Results
–Test of stored blood may help answer troubling questions about the trial. A new analysis of stored blood by the ROCKET AF trial investigators may…
New Studies Seek To Allay Concerns Over The ROCKET-AF Trial
New post-hoc analyses of ROCKET-AF confirm the main results of the controversial trial, according to a paper published in the New England Journal of Medicine.…
ROCKET-AF Investigators Seek To Calm Concerns About Trial Reliability
(Updated) In response to disturbing questions about the integrity and reliability of crucial data in the ROCKET AF trial, the executive committee of the trial has released a…
New Questions Raised About ROCKET AF, Pivotal Xarelto Trial Chaired By Califf
(Updated) Disturbing questions are being raised about the integrity and reliability of crucial data in the ROCKET AF trial. The investigation could have important implications…
Boehringer Ingelheim’s Pradaxa Gains New Indication
The new oral anticoagulants continue to gain additional indications from the FDA. Earlier today Boehringer Ingelheim announced that the FDA had approved Pradaxa (dabigatran) for the treatment…